Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc > GTX-104 positive results

<< Previous

Bullboard Posts

Next >>

Comment by Canadian_101on Nov 21, 2022 3:26pm

204 Views

Post# 35116548

RE:GTX-104 positive results

No One is paying attention to them, look at the decline in share price, its hard to believe they are still around, glad I dumped when they delayed their results for capri, I would not invest a dime in this company, no credibility at all.

bingostar wrote: As annouced today:

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints :: Acasti Pharma Inc. (ACST)

They have 3 products going in phase 3 and the company is trading under the cash value.